- Presentations
- 6
- Markets
- 1
Skyrizi is a brand of Risankizumab marketed by AbbVie, with 6 presentations listed and registered in United States. Each presentation below has its own page with packs, documents and availability for export supply from India.
- Active ingredient (INN)
- Risankizumab
- Brand owner
- AbbVie
- Registered in
- United States
- Strengths and forms
- 150 mg/1 mL injection, 180 mg/1.2 mL injection, 55 mg/0.37 mL injection, 600 mg/10 mL injection, kit
All presentations
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Skyrizi 150 mg/1 mL injectionSubcutaneous Cold chain | AbbVie | US FDA | Available on request |
| Skyrizi 180 mg/1.2 mL injectionSubcutaneous Cold chain | AbbVie | US FDA | Available on request |
| Skyrizi 55 mg/0.37 mL injectionSubcutaneous Cold chain | AbbVie | US FDA | Available on request |
| Skyrizi 600 mg/10 mL injectionIntravenous Cold chain | AbbVie | US FDA | Available on request |
| Skyrizi kitIntravenous Cold chain | AbbVie | US FDA | Available on request |
| Skyrizi kit Cold chain | AbbVie | US FDA | Available on request |
Brand names and trademarks belong to their owners and are used only to identify products.
Request Skyrizi
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.